Ipilimumab vs Pembrolizumab

## Ipilimumab vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between **Ipilimumab** and **Pembrolizumab**.

## Mechanism of Action

**Ipilimumab**: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

**Pembrolizumab**: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

## Pharmacokinetics

**Half-life**: Ipilimumab — 14.7 days; Pembrolizumab — 26 days.

## Chemical Properties

**Type**: Ipilimumab — Antibody; Pembrolizumab — Antibody.